Zydus Cadila Has Received Tentative Approval From Us Food And Drug Administration (Fda) To Market Tofacitinib Extended-Release Tablets, 11 Mg.It Is Recommended For The Once-Daily Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis (Uc).The Drug Will Be Manufactured At The Group'S Formulation Manufacturing Facility At The Sez, Ahmedabad.The Group Now Has 308 Approvals And Has So Far Filed Over 390 Andas Since The Commencement Of The Filing Process In Fy 2003-04.
